Adolor shares in meltdown on trial data

Researchers at Adolor have received mixed signals from two Phase III trials of alvimopan to treat opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. One study hit its primary endpoint and the other failed to achieve statistical significance. That news sent investors for the exits, sending Adolor's stock down 54 percent. Alvimopan, which is Adolor's lead product and is being developed in collaboration with GlaxoSmithKline, also failed a Phase IIb trial for cancer pain. Adolor, though, noted that the late-stage failure came in a trial that hit its secondary endpoint for a change in frequency of spontaneous bowel movements. In that study, 63 percent of participants taking alvimopan met the primary endpoint compared to 56 percent of patients taking a placebo.

- here's the report on Adolor from MarketWatch

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.